A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
Condition or disease
Incontinence, Urinary and Urinary Bladder, OveractiveOveractive Bladder
Drug: GW679769 oral tablets
A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced Titration, Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of 60 mg and 120 mg of GW679769 administered once daily vs Placebo in Women with Overactive Bladder
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Female subjects with overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain.
Must not be pregnant.
Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol.
Body weight in the range of = 45 kg and <100 kg.
Stage III/IV pelvic organ prolapse with or without cystocele.
History of interstitial cystitis or bladder related pain.
Subjects with stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history.
History of pelvic prolapse repair (cystocele or rectocele) or urethral diverticulectomy within six months of screening.
Subjects with urinary incontinence due to causes other then detrusor over activity (e.g., overflow incontinence).
Nocturnal enuresis only.
Urinary retention, or other evidence of poor detrusor function.
History of prior anti-incontinence surgery.
History of radiation cystitis or a history of pelvic irradiation.
Electrostimulation, biofeedback, or bladder training therapy (behavioral therapy) during the previous month prior to screening, or the intention to initiate such therapies during the study. Pessaries and implants are also excluded.
Participated in any clinical trial of an investigation drug that may affect urinary function within 3 months of enrollment into the study.
Received any investigational product within 30 days of enrollment into the study.